Slide 1: Q3-2013 Earnings Release
Q3-2013 Earnings Release
Slide 2: Forward-looking statements
This presentation contains forward-looking statements (made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995). By their nature, forward- looking statements involve risk and uncertainty. Forward-looking statements represent the company's judgment regardi
Slide 3: This document should not be distributed without Cegedim authorization – Copyright 2013
This document should not be distributed without Cegedim authorization – Copyright 2013 3
Slide 4: 9M-2013: Key Take Aways
ו9M-2013: Key Take Aways This document should not be distributed without Cegedim authorization – Copyright 2013 4
Slide 5: Q3-2013 Key Figures per Division
וQ3-2013 Key Figures per Division This document should not be distributed without Cegedim authorization – Copyright 2013 5
Slide 6: 9M-2013 Key Figures per Division
ו9M-2013 Key Figures per Division This document should not be distributed without Cegedim authorization – Copyright 2013 6
Slide 7: 9M Group Key figures
ו9M Group Key figures This document should not be distributed without Cegedim authorization – Copyright 2013 7
Slide 8: 9M 2013 Group Revenue
ו9M 2013 Group Revenue This document should not be distributed without Cegedim authorization – Copyright 2013 8
Slide 9: All Divisions Posted L-f-L Revenue Growth in Q3 2013
וAll Divisions Posted L-f-L Revenue Growth in Q3 2013 This document should not be distributed without Cegedim authorization – Copyright 2013 9
Slide 10: Expenses Continued to Decrease in Q3
וExpenses Continued to Decrease in Q3 This document should not be distributed without Cegedim authorization – Copyright 2013 10
Slide 11: EBITDA Evolution per Division
וEBITDA Evolution per Division This document should not be distributed without Cegedim authorization – Copyright 2013 11
Slide 12: From EBITDA to EBIT
וFrom EBITDA to EBIT This document should not be distributed without Cegedim authorization – Copyright 2013 12
Slide 13: From EBIT to Consolidated Net Profit
וFrom EBIT to Consolidated Net Profit This document should not be distributed without Cegedim authorization – Copyright 2013 13
Slide 14: 9M 2013 Simplified Balance Sheet
ו9M 2013 Simplified Balance Sheet This document should not be distributed without Cegedim authorization – Copyright 2013 14
Slide 15: 9M 2013 Net Debt Evolution
ו9M 2013 Net Debt Evolution This document should not be distributed without Cegedim authorization – Copyright 2013 15
Slide 16: Cegedim Strives for Realistic Mid Term Group Targets
וCegedim Strives for Realistic Mid Term Group Targets This document should not be distributed without Cegedim authorization – Copyright 2013 16
Slide 17: FY 2013 Outlook
וFY 2013 Outlook This document should not be distributed without Cegedim authorization – Copyright 2013 17
Slide 18: Financial Agenda
וFinancial Agenda This document should not be distributed without Cegedim authorization – Copyright 2013 18
Slide 19: 2014 Financial Agenda
ו2014 Financial Agenda This document should not be distributed without Cegedim authorization – Copyright 2013 19
Slide 20: Appendix
Appendix
Slide 21: Revenue & Organic Growth Calculation
וRevenue & Organic Growth Calculation in thousands of euro Q3‐2013 Division 1 Division 2 Division 3 Group 2012 Revenue a 111 113 62 623 33 848 207 584 Impact of disposals 0 0 0 0 2012 Revenue before impact of disposals 111 113 62 623 33 848 207 584 Currency impact (5 015) (1 332) (3) (6 350) 2012
Slide 22: Revenue by Division and by Quarter
וRevenue by Division and by Quarter in thousands of euro Year 2013 Q1 Q2 Q3 Q4 Total CRM and Strategic Data 104,641 109,985 108,106 322,732 Healthcare Professionals 71,032 74,528 65,292 210,852 Insurance and Services 37,192 39,850 37,617 114,659 Cegedim 212,865 224,363 211,014 648,243 Year 2012 Q
Slide 23: CRM & Strategic Data 9M 2013 Revenue
ו CRM & Strategic Data 9M 2013 Revenue Growth in the third quarter was attributable to: Catching up on a significant portion of the market research studies postponed in June Start-up of several new CRM projects, despite the pharmaceutical industry’s changing model OneKey database, notably in
Slide 24: Healthcare Professionals 9M-2013 Revenue
ו Healthcare Professionals 9M-2013 Revenue Computerization activities for doctors, physical therapists and nurses are developing nicely in Europe, particularly in France, where healthcare professional software design orders made up lost ground, as expected Increase was partly offset by a wait-
Slide 25: Insurance and Services 9M 2013 Revenue
וInsurance and Services 9M 2013 Revenue All of the division’s activities contributed to the growth: Cegedim Assurances posted significant third-quarter growth Cegedim SRH continues to garner numerous commercial successes, resulting in double-digit growth Cegedim e-business is experiencing s
Slide 26: Business Seasonality
וBusiness Seasonality Traditionally higher sales on software at the end of the year Spending of remaining operating budget More use of data and market research in Q4 due to the reorganization of sales force, organization of new campaign, annual reporting,… This document should not be distri
Slide 27: Financial Overview
וFinancial Overview This document should not be distributed without Cegedim authorization – Copyright 2013 27
Slide 28: Cegedim is a group with solid foundations
וCegedim is a group with solid foundations This document should not be distributed without Cegedim authorization – Copyright 2013 28
Slide 29: Keep in Touch with Cegedim
וKeep in Touch with Cegedim This document should not be distributed without Cegedim authorization – Copyright 2013 29
Slide 30: We welcome your questions and comments
We welcome your questions and comments Jan Eryk UMIASTOWSKI Chief Investment Officer Head of Investor Relations Janeryk.umiastowski@cegedim.com www.cegedim.com/finance TEL: +33 (0) 1 49 09 33 36